View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 18, 2020

Russia begins post-registration trials of EpiVacCorona Covid-19 vaccine

Russia has launched the post-registration trials of EpiVacCorona, a Covid-19 vaccine candidate developed by the State Research Center of Virology and Biotechnology, Vector.

Russia has launched the post-registration trials of EpiVacCorona, a Covid-19 vaccine candidate developed by the State Research Center of Virology and Biotechnology, Vector.

The vaccine does not contain the live virus and develops immunity by using artificially synthesised peptides.

In July, the Vector Research Centre got Russian Health Ministry approval to carry out the human trials of the vaccine and the first volunteer received the vaccine shot on 27 July.

Russian Federal Service Oversight of Consumer Protection and Welfare head Anna Popova was quoted by TASS news agency as saying: “We can only stop the spread (of Covid-19) through vaccination.

“On October 13, the Epivaccorona vaccine based on peptide antigens has been registered, right now, the third stage of post-registration trials is underway.”

EpiVacCorona is the second Covid-19 vaccine to receive approval from the Russian authorities.

In August, Russia became the first country to grant regulatory approval to a Covid-19 vaccine when Sputnik V was officially registered ahead of large-scale trials.

Earlier, Russian Deputy Prime Minister Tatyana Golikova had said that she tested EpiVacCorona vaccine herself and no side effects were experienced.

Last week, the Russian Direct Investment Fund (RDIF) and Gamaleya Center announced that a first interim analysis of Phase III trials of the Sputnik V vaccine demonstrated 92% efficacy in Covid-19 patients.

The interim data was based on the double-blind, randomised, placebo-controlled trials. They analysed the efficacy among 16,000 participants who were given the vaccine or placebo 21 days after the first injection.

Sputnik V is the first registered vaccine against the disease created on a human adenoviral vector platform.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena